Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive

image via TechCrunch

March 31, 2025, 8:58 PM

• •Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time.
• •The $600 million round was led by Thrive Capital, with participation from GV and existing investor Alphabet, Google’s parent.
• •The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical trials.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised external capital for the first time. The $600 million round was led by Thrive Capital, with participation from GV and existing investor Alphabet, Google’s parent, it said. The funding will accelerate further development of Isomorphic’s AI drug design engine and support the company’s goal of bringing its discovered drugs to clinical trials.

Read original article